Written by Olivia Farrow, RD, MHSc Reviewed by Krista Kolodziejzyk, RD, MPH, MBA and Maria Dellanina, RDN Quick Links If you are a dietitian working in client nutrition counseling, chances are youve had at least one client mention GLP-1 medications in the past few months
Per Humana's pharmacy policy (effective 1/20/2025), coverage requires ALL of the following: [4] Moderate-to-severe OSA diagnosis (AHI 15 on polysomnogram or REI 15 on home sleep test) BMI 27 kg/m (lower threshold than FDA label's obesity requirement) Using Zepbound with lifestyle modifications (reduced-calorie diet + physical activity) NO diabetes diagnosis (type 1 or type 2)this is an exclusion criterion Use diagnosis code G47.33 for OSA as the primary diagnosis, with obesity as secondary
Final Words Each type of transdermal patch has its unique advantages and applications, tailored to the specific properties of the medication and the therapeutic needs of the patient
For vomiting, tirzepatide posed the highest risk (relative risk 13.22), followed by semaglutide (4.21) and liraglutide (3.87)
It is a roadmap for a process that unfolds over months, adapting to your body, your tolerance, and your goals
Denny O, Baron J, Albanese NP
